margetuximab

01/01/2023 - "Further studies evaluating the efficacy and safety of margetuximab in Chinese HER2-positive breast cancer patients are needed."
05/01/2023 - "Margetuximab in HER2-positive metastatic breast cancer."
01/01/2022 - "Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer."
09/01/2021 - "In this monograph we recapitulate the clinical development, current role and future perspectives of margetuximab for the treatment of breast cancer."
09/01/2021 - "Clinical development and current role of margetuximab for the treatment of breast cancer."

11/01/2023 - "In patients with HER2+ tumors treated with tebotelimab plus margetuximab, 74% (62/84) had TRAEs (17% were grade ≥3). "
11/01/2023 - "To enhance potential anti-tumor responses, we tested margetuximab plus tebotelimab. "
05/01/2023 - "The tail region of margetuximab has been changed to boost the immune responses against HER2-positive cancer cells. "
10/01/2022 - "MAHOGANY cohort A part 1 is a single-arm trial to evaluate margetuximab plus retifanlimab in patients with HER2 immunohistochemistry 3+, PD-L1-positive (combined positive score ≥1%), and non-microsatellite instability-high tumors. "
01/01/2022 - "Ongoing studies are assessing the role of margetuximab in other settings and diseases such as early stage breast cancer and gastrointestinal malignancies. "

04/01/2021 - "MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma."
04/01/2021 - "Here, we describe the design and rationale of the randomized, open-label, Phase II/III MAHOGANY trial evaluating margetuximab plus retifanlimab with/without chemotherapy and margetuximab plus tebotelimab with chemotherapy in first-line unresectable metastatic/locally advanced gastroesophageal junction adenocarcinoma. "
10/01/2022 - "Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A."
01/01/2020 - "Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial."
01/01/2020 - "We aimed to evaluate the safety, tolerability, and antitumour activity of margetuximab plus pembrolizumab (an anti-PD-1 monoclonal antibody) in previously treated patients with HER2-positive gastro-oesophageal adenocarcinoma. "

07/01/2021 - "Cardiotoxicity rates of other HER2-targeted treatments, such as pertuzumab, T-DM1, lapatinib, neratinib, tucatinib, trastuzumab deruxtecan, and margetuximab, appear to be significantly lower as reported in the pivotal trials which led to their approval. "

10/01/2022 - "MAHOGANY cohort A part 1 is a single-arm trial to evaluate margetuximab plus retifanlimab in patients with HER2 immunohistochemistry 3+, PD-L1-positive (combined positive score ≥1%), and non-microsatellite instability-high tumors. "